ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says

ANI Pharmaceuticals (NASDAQ:ANIP) had its target price increased by Truist Financial from $62.00 to $65.00 in a report issued on Monday morning,Benzinga reports. Truist Financial currently has a hold rating on the specialty pharmaceutical company’s stock.

Several other research firms have also recently weighed in on ANIP. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 16th. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $68.00 on Monday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business’s 50 day moving average price is $63.43 and its two-hundred day moving average price is $59.53. The company has a market cap of $1.48 billion, a PE ratio of -123.64 and a beta of 0.49. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.48.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares of the company’s stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 over the last quarter. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Millennium Management LLC lifted its stake in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after buying an additional 473,097 shares in the last quarter. JPMorgan Chase & Co. lifted its position in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares in the last quarter. abrdn plc acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $13,155,000. Deep Track Capital LP increased its holdings in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after purchasing an additional 144,214 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.